These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8851590)

  • 21. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical liposomal delivery of antibiotics in soft tissue infection.
    Price CI; Horton JW; Baxter CR
    J Surg Res; 1990 Aug; 49(2):174-8. PubMed ID: 2381207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrin-enmeshed tobramycin liposomes: single application topical therapy of Pseudomonas keratitis.
    Frucht-Perry J; Assil KK; Ziegler E; Douglas H; Brown SI; Schanzlin DJ; Weinreb RN
    Cornea; 1992 Sep; 11(5):393-7. PubMed ID: 1424666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
    Máiz L; Girón RM; Olveira C; Quintana E; Lamas A; Pastor D; Cantón R; Mensa J
    Expert Opin Pharmacother; 2013 Jun; 14(9):1135-49. PubMed ID: 23586963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition.
    Beaulac C; Clement-Major S; Hawari J; Lagace J
    J Microencapsul; 1997; 14(3):335-48. PubMed ID: 9147283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against
    Alzahrani NM; Booq RY; Aldossary AM; Bakr AA; Almughem FA; Alfahad AJ; Alsharif WK; Jarallah SJ; Alharbi WS; Alsudir SA; Alyamani EJ; Tawfik EA; Alshehri AA
    Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of mucoid coating on clearance of Pseudomonas aeruginosa from lungs.
    Blackwood LL; Pennington JE
    Infect Immun; 1981 May; 32(2):443-8. PubMed ID: 6788696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Barclay ML; Begg EJ; Chambers ST; Thornley PE; Pattemore PK; Grimwood K
    J Antimicrob Chemother; 1996 Jun; 37(6):1155-64. PubMed ID: 8836818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
    McCrae WM; Raeburn JA; Hanson EJ
    J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
    Croisier D; Martha B; Piroth L; Chavanet P
    Int J Antimicrob Agents; 2008 Dec; 32(6):494-8. PubMed ID: 18804348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokinetic-Pharmacodynamic Modeling for Evaluation of Treatments against Chronic
    Sou T; Kukavica-Ibrulj I; Levesque RC; Friberg LE; Bergström CAS
    Mol Pharm; 2020 May; 17(5):1458-1469. PubMed ID: 31951139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis.
    Martin AJ; Smalley CA; George RH; Healing DE; Anderson CM
    Arch Dis Child; 1980 Aug; 55(8):604-7. PubMed ID: 7436516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
    Chuchalin A; Amelina E; Bianco F
    Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
    Crozier DN; Khan SR
    J Infect Dis; 1976 Aug; 134 Suppl():S187-90. PubMed ID: 823275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.
    Orizondo RA; Babcock CI; Fabiilli ML; Pavlovsky L; Fowlkes JB; Younger JG; Cook KE
    J Aerosol Med Pulm Drug Deliv; 2014 Oct; 27(5):392-9. PubMed ID: 24476046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subinhibitory antibiotics reduce Pseudomonas aeruginosa tissue injury in the rat lung model.
    Grimwood K; To M; Rabin HR; Woods DE
    J Antimicrob Chemother; 1989 Dec; 24(6):937-45. PubMed ID: 2516085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.